Molecular Markers and Chemotherapy for Advanced Salivary Cancer

被引：11
|
作者：
Vander Poorten V. [1 ,2 ,3 ,6 ]
Meulemans J. [1 ]
Delaere P. [1 ,2 ]
Nuyts S. [2 ,4 ,6 ]
Clement P. [2 ,5 ,6 ]
机构：
[1] Otorhinolaryngology-Head and Neck Surgery, University Hospitals Leuven, Herestraat 49, Leuven
[2] Leuven Cancer Institute, University Hospitals Leuven, Herestraat 49, Leuven
[3] European Salivary Gland Society, Geneva
[4] Radiation Oncology, University Hospitals Leuven, Herestraat 49, Leuven
[5] Medical Oncology, University Hospitals Leuven, Herestraat 49, Leuven
[6] Section Head and Neck Oncology, Department of Oncology, KULeuven, Herestraat 49, Leuven
来源：
Current Otorhinolaryngology Reports | 2014年 / 2卷 / 2期
关键词：
Chemotherapy; Molecular biology; Molecular markers; Salivary gland cancer; Salivary gland neoplasms; Targeted therapy;
D O I：
10.1007/s40136-014-0040-2
中图分类号：
学科分类号：
摘要：
Recent advances in our understanding of the molecular biology of salivary gland neoplasms have yielded diagnostic targets and potential therapeutic targets that have started to change our approach and choice of treatment strategies. Currently, these options are mainly investigated in recurrent and metastatic salivary gland cancer (SGC). Although the results of both cytotoxic and targeted molecular biological systemic therapy for locoregional recurrence and distant spread of SGC remain largely unpredictable, targeted therapy can be the treatment of choice in selected cases today. Molecular analysis is required as part of the diagnostic workup to help select patients with recurrent and metastatic SGC who may benefit from targeted or standard treatment regimens. © 2014, Springer Science+Business Media New York.
引用
收藏
页码：85 / 96
页数：11
相关论文
共 50 条
  • [1] Molecular prognostic markers for survival after chemotherapy in advanced bladder cancer
    Als, A. B.
    Koed, K.
    Jensen, J. L.
    Dyrskjot, L.
    Orntoft, T. F.
    von der Meese, H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 228 - 229
  • [2] Molecular markers of chemotherapy in advanced colorectal cancer: Back to square one
    Sobrero, Alberto
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1902 - 1903
  • [3] Molecular Markers of Chemotherapy Response in Colorectal Cancer
    Braun, Michael S.
    Seymour, Matthew T.
    CURRENT COLORECTAL CANCER REPORTS, 2010, 6 (03) : 118 - 125
  • [4] Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer
    Braun, Michael S.
    Seymour, Matthew T.
    CURRENT COLORECTAL CANCER REPORTS, 2011, 7 (01) : 105 - 111
  • [5] Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer (FOCUS).
    Seymour, M. T.
    Braun, M. S.
    Richman, S. D.
    Daly, C.
    Thompson, L. C.
    Meade, A.
    Parmar, M.
    Allan, J. M.
    Selby, P.
    Quirke, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 84S - 84S
  • [6] Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial
    Braun, Michael S.
    Richman, Susan D.
    Thompson, Lindsay
    Daly, Catherine L.
    Meade, Angela M.
    Adlard, Julian W.
    Allan, James M.
    Parmar, Mahesh K. B.
    Quirke, Philip
    Seymour, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5519 - 5528
  • [7] Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer
    Shiovitz S.
    Grady W.M.
    Current Gastroenterology Reports, 2015, 17 (2)
  • [8] Molecular prognostic markers in locally advanced colon cancer
    Lurje, Georg
    Zhang, Wu
    Lenz, Heinz-Josef
    CLINICAL COLORECTAL CANCER, 2007, 6 (10) : 683 - 690
  • [9] Commentary on the work Place of chemotherapy in the treatment of advanced or recurrent salivary gland cancer
    Kawecki, Andrzej
    ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (03): : 111 - 112
  • [10] Molecular markers in gastrointestinal cancer: Targeted therapy and tailored chemotherapy
    Lenz, HJ
    ONKOLOGIE, 2004, 27 (01): : 12 - 14
12345